MS-Krankheit--Multiple Sklerose ist eine Nervenkrankheit woran..... - 500 Beiträge pro Seite
eröffnet am 14.09.09 12:02:51 von
neuester Beitrag 17.09.10 19:58:05 von
neuester Beitrag 17.09.10 19:58:05 von
Beiträge: 11
ID: 1.153.001
ID: 1.153.001
Aufrufe heute: 0
Gesamt: 1.188
Gesamt: 1.188
Aktive User: 0
ISIN: SE0001137985 · WKN: A0BLFX
0,0485
EUR
-3,77 %
-0,0019 EUR
Letzter Kurs 07.05.24 Lang & Schwarz
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 1,1600 | +40,52 | |
| 4,6900 | +28,49 | |
| 5,1200 | +28,00 | |
| 1,4799 | +26,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7212 | -16,89 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Feedback
ÃBER MULTIPLE SKLEROSE
Multiple Sklerose (MS) ist die führende Ursache der neurologischen Behinderung in young Adults. Es wird geschätzt, dass mehr als 400.000 Menschen in den Vereinigten Staaten von der Seuche betroffen sind und, dass zwei Millionen Menschen weltweit beeinträchtigt werden können. MS ist eine Progressive, demyelinisierende Krankheiten des Zentralnervensystems, die Auswirkungen auf das Gehirn, Rückenmark und Optik Nerven. Demyelination ist die destruktiven Aufschlüsselung der dem fetthaltigen Gewebe, das Nervus Endungen schützt
Multiple Sklerose (MS) ist die führende Ursache der neurologischen Behinderung in young Adults. Es wird geschätzt, dass mehr als 400.000 Menschen in den Vereinigten Staaten von der Seuche betroffen sind und, dass zwei Millionen Menschen weltweit beeinträchtigt werden können. MS ist eine Progressive, demyelinisierende Krankheiten des Zentralnervensystems, die Auswirkungen auf das Gehirn, Rückenmark und Optik Nerven. Demyelination ist die destruktiven Aufschlüsselung der dem fetthaltigen Gewebe, das Nervus Endungen schützt
Antwort auf Beitrag Nr.: 37.973.131 von Big Charly am 14.09.09 12:02:51Das Problem dürfte vom ungehemmten Spritzmitteleinsatz bei der Nahrungsmittelproduktion herrühren. (Botenstoffveränderungen)
Antwort auf Beitrag Nr.: 37.974.814 von Dorfrichter am 14.09.09 15:32:05dies ist keine moderne, aus jüngster zeit, entstandene Krankheit
Diese Krankheit kenne ich aus meiner Familie schon aus den 60er.
Diese Nervenlähmung ist bis heute, wie der Krebs, noch nicht ganz erforscht.
Diese Krankheit kenne ich aus meiner Familie schon aus den 60er.
Diese Nervenlähmung ist bis heute, wie der Krebs, noch nicht ganz erforscht.
Antwort auf Beitrag Nr.: 37.975.206 von Big Charly am 14.09.09 16:07:02Ende der 60er, nehme ich wohl an.
Trading Spotlight
Active Biotech AB - Company Announcement
Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II clinical study of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate
cancer.
In this analysis, safety, efficacy and certain biomarkers were evaluated. The primary endpoint, to show a difference in the number of patients with disease progression at six months, was reached. The fraction of patients with disease progression during the six month
period was 43 % for patients treated with TASQ compared to 67 % for placebo reated patients. The median progression free survival was 24.7 weeks for the TASQ group, compared to 12.9 weeks (p=0.0001) for the placebo group. TASQ treatment also had a positive effect on several
biomarkers relevant for prostate cancer progression and was generally well tolerated. No safety concerns significantly affecting the risk/benefit ratio for TASQ were identified.
"This is a very important milestone for TASQ and Active Biotech. I am looking forward to the further development of this novel,non-cytotoxic treatment. ", says Professor Tomas Leanderson, CEOActive Biotech ".
The top line data are based on the local review of disease progression and an additional central review is currently ongoing.
Complete results from the trial including additional details and data from the central review will be presented at an upcoming scientific conference and in scientific publications.
Lund, December 14, 2009
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.acti…
Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II clinical study of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate
cancer.
In this analysis, safety, efficacy and certain biomarkers were evaluated. The primary endpoint, to show a difference in the number of patients with disease progression at six months, was reached. The fraction of patients with disease progression during the six month
period was 43 % for patients treated with TASQ compared to 67 % for placebo reated patients. The median progression free survival was 24.7 weeks for the TASQ group, compared to 12.9 weeks (p=0.0001) for the placebo group. TASQ treatment also had a positive effect on several
biomarkers relevant for prostate cancer progression and was generally well tolerated. No safety concerns significantly affecting the risk/benefit ratio for TASQ were identified.
"This is a very important milestone for TASQ and Active Biotech. I am looking forward to the further development of this novel,non-cytotoxic treatment. ", says Professor Tomas Leanderson, CEOActive Biotech ".
The top line data are based on the local review of disease progression and an additional central review is currently ongoing.
Complete results from the trial including additional details and data from the central review will be presented at an upcoming scientific conference and in scientific publications.
Lund, December 14, 2009
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.acti…
Antwort auf Beitrag Nr.: 38.562.844 von aktianer am 14.12.09 14:28:25zweiter Verlink-Versuch zu der erfreulichen TASQ-Meldung:
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=377693&messageId=452112
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=377693&messageId=452112
Antwort auf Beitrag Nr.: 38.562.988 von aktianer am 14.12.09 14:48:15ich geb noch nicht auf, 3.Versuch, jetzt auf den Firmenlink:
http://activebiotech.com/?oid=newsdetail&news=1360883&_local…
http://activebiotech.com/?oid=newsdetail&news=1360883&_local…
News zu Laquinimod und Kapitalerhöhung unter Ausschluß der Aktionäre durch Investor, erfreulicherweise nahe dem aktuellen Kurs zu 105 SEK anfangs April:
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
15 Apr, 2010 18:31 CET
NEW DATA SUGGEST ORAL LAQUINIMOD MAY CONFER NEUROPROTECTION IN ADDITION TO IMMUNOMODULATION IN THE TREATMENT OF MULTIPLE SCLEROSIS
- Enhanced levels of brain derived neurotrophic factor, possibly
contributing to neuroprotection, were shown in laquinimod treated multiple sclerosis (MS) patients
-Laquinimod significantly reduce demyelination and axonal damage as
shown in animal models
-Two ongoing pivotal, global phase III clinical trials are fully
enrolled and results are anticipated next year
http://www.cisionwire.com/ext/active-biotech/new-data-sugges…
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
01 Apr, 2010 15:00 CET
Active Biotech raises SEK 149 million through a directed share ssue
The Board of Directors of Active Biotech has, pursuant to the authorization given by the 2009 annual general meeting, resolved today to issue a total of 1,418,000 new shares in Active Biotech.
The issue is completed by means of a directed share issue placed with funds managed by Sectoral Asset Management Inc., a global investment manager in the healthcare sector. The shares are issued at a subscription price of SEK 105 per share, which means that the issue proceeds amounts to approximately SEK 149 million before issue expenses. The subscription price was determined on the
basis of the current market price of the Active Biotech share on NASDAQ OMX Stockholm and corresponds to the average closing price of the Active Biotech shares during the preceding thirty trading days.
http://www.cisionwire.com/ext/active-biotech/active-biotech-…
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
15 Apr, 2010 18:31 CET
NEW DATA SUGGEST ORAL LAQUINIMOD MAY CONFER NEUROPROTECTION IN ADDITION TO IMMUNOMODULATION IN THE TREATMENT OF MULTIPLE SCLEROSIS
- Enhanced levels of brain derived neurotrophic factor, possibly
contributing to neuroprotection, were shown in laquinimod treated multiple sclerosis (MS) patients
-Laquinimod significantly reduce demyelination and axonal damage as
shown in animal models
-Two ongoing pivotal, global phase III clinical trials are fully
enrolled and results are anticipated next year
http://www.cisionwire.com/ext/active-biotech/new-data-sugges…
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
01 Apr, 2010 15:00 CET
Active Biotech raises SEK 149 million through a directed share ssue
The Board of Directors of Active Biotech has, pursuant to the authorization given by the 2009 annual general meeting, resolved today to issue a total of 1,418,000 new shares in Active Biotech.
The issue is completed by means of a directed share issue placed with funds managed by Sectoral Asset Management Inc., a global investment manager in the healthcare sector. The shares are issued at a subscription price of SEK 105 per share, which means that the issue proceeds amounts to approximately SEK 149 million before issue expenses. The subscription price was determined on the
basis of the current market price of the Active Biotech share on NASDAQ OMX Stockholm and corresponds to the average closing price of the Active Biotech shares during the preceding thirty trading days.
http://www.cisionwire.com/ext/active-biotech/active-biotech-…
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Projektpräsentationen von Active Biotech am 14.Sept.2010 in den USA:
09.09.2010 08:32 Active Biotech: Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
Lund, Sweden, September 9, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman&Renshaw 12th Annual Healthcare Conference on Tuesday, September 14 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.
The presentation will include projects in or entering Phase III; laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com (http://www.activebiotech.com/).
The presentation will take place on September 14, at 2:25 pm US Eastern Daylight Time / 20:25 Central European Summer Time.
09.09.2010 08:32 Active Biotech: Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
Lund, Sweden, September 9, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman&Renshaw 12th Annual Healthcare Conference on Tuesday, September 14 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.
The presentation will include projects in or entering Phase III; laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com (http://www.activebiotech.com/).
The presentation will take place on September 14, at 2:25 pm US Eastern Daylight Time / 20:25 Central European Summer Time.
Antwort auf Beitrag Nr.: 37.975.357 von Dorfrichter am 14.09.09 16:17:40ich weiss zwar nicht woher du dein wissen hast
aber wie geschrieben
mein Vater verstarb 1962 an dieser Krankheit und hat NUR vier Jahre unter dieser krankheit leiden müssen.
Die Krankheit bekommst du in jungen jahren, verläuft in Schüben und kann........
aber wie geschrieben
mein Vater verstarb 1962 an dieser Krankheit und hat NUR vier Jahre unter dieser krankheit leiden müssen.
Die Krankheit bekommst du in jungen jahren, verläuft in Schüben und kann........
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,45 | |
| +1,31 | |
| +1,74 | |
| +2,43 | |
| +1,25 | |
| +0,22 | |
| +3,97 | |
| +2,19 | |
| +0,30 | |
| +2,04 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 298 | ||
| 142 | ||
| 102 | ||
| 94 | ||
| 64 | ||
| 64 | ||
| 56 | ||
| 54 | ||
| 43 | ||
| 42 |
